Genmab climbs on Phase II daratumumab data

Genmab A/S (CSE:GEN; OTCBB:GMXAY) rose DKK46 (11%) to DKK471 in Copenhagen after partner Janssen Biotech Inc. reported preliminary results from a Phase II trial of daratumumab in relapsed or refractory multiple myeloma (MM) patients.

The mAb against CD38 showed a 29.2% overall response rate and 7.4 month median duration of response in relapsed or refractory MM patients in the study's 16 mg/kg dosing group. The unit of Johnson & Johnson (NYSE:JNJ) did not report results from the trial's 8 mg/kg dosing group and J&J spokesperson Kellie McLaughlin declined to tell BioCentury whether daratumumab met the trial's primary endpoint. ...